Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | SLC5A2 | P31639 | 16/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305988 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL29534778 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL29394990 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL29627364 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL29414951 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL152362 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL152361 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL153622 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL9949259 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL98837 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240759-A1 | IMMUNE COMPOSITION COMPRISING ANTIGEN AND GLYCOENGINEERED ANTIBODY THEREOF | Cho Pharma Inc (TW) | 2023-09-13 | — | — | EP | claimed |
| WO-2022099307-A1 | IMMUNE COMPOSITION COMPRISING ANTIGEN AND GLYCOENGINEERED ANTIBODY THEREOF | CHO PHARMA, INC. (TW) | 2022-05-12 | — | — | WO | claimed |
| US-20260060975-A1 | INHIBITING MUTANT IDH-1 | FORMA THERAPEUTICS, INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260014138-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | FORMA THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260000664-A1 | TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE-1 (IDH-1) MUTATION | FORMA THERAPEUTICS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250172545-A1 | METHOD FOR EXTRACTING AND IDENTIFYING POLYSACCHARIDE FROM COMPLEX SAMPLE | ZHEJIANG UNIVERSITY (CN) | 2025-05-29 | — | — | US | disclosed |
| US-12265082-B2 | Detecting microbial infection in wounds | SYNOVO GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| US-20250082628-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | FORMA THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| CN-114746434-B | Antibiotic compounds | 莱顿大学 | 2025-02-21 | — | — | CN | disclosed |
| US-20240148718-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | FORMA THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11963956-B2 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | FORMA THERAPEUTICS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-2428581-B1 | Method for identifying at least two groups of microorganisms | BIOMERIEUX SA (FR) | 2013-10-09 | — | — | EP | disclosed |
| US-8420345-B2 | Method for identifying at least two groups of microorganisms | BIOMERIEUX (FR) | 2013-04-16 | — | — | US | disclosed |
| EP-2428581-A1 | Method for identifying at least two groups of microorganisms | Biomérieux (FR) | 2012-03-14 | — | — | EP | disclosed |
| US-20090017481-A1 | Method For Identifying at Least Two Groups of Microorganisms | BIOMERIEUX (FR) | 2009-01-15 | — | — | US | disclosed |
| EP-1989321-A2 | METHOD FOR IDENTIFYING AT LEAST TWO GROUPS OF MICROORGANISMS | BIOMERIEUX (FR) | 2008-11-12 | — | — | EP | disclosed |
| EP-0870054-B1 | METHOD AND COMPOSITION FOR DETECTING BACTERIAL CONTAMINATION IN FOOD PRODUCTS | BIOCONTROL SYSTEMS INC (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007099254-A2 | METHOD FOR IDENTIFYING AT LEAST TWO GROUPS OF MICROORGANISMS | BIOMERIEUX (FR) | 2007-09-07 | — | — | WO | disclosed |
| US-6472167-B1 | MEASURE VIABLE BACTERIA AS A FUNCTION OF THE ACTIVITIES OF BACTERIAL ENZYMES, PHOSPHATASES, GLUCOSIDASES, AND AMINOPEPTIDASES; PRESENCE DETECTED BY A FLUORESCENT SIGNAL | BIOCONTROL SYSTEMS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6387650-B1 | INNOCULATING AND INCUBATING TEST SAMPLE ON GROWTH MEDIUM HAVING ENZYME SUBSTRATES FOR PHOSPHATASE, GLYCOSIDASE, AND PEPTIDASE, THEN DETECTING OR MEASURING SIGNAL PRODUCED BY THE HYDROLYSIS OF THE SUBSTRATES | BIOCONTROL SYSTEMS, INC. | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060975-A1 | INHIBITING MUTANT IDH-1 | IDH3B, IDH1, MCL1 | ATM 159/4885SLC5A2 1823/4885SLC5A1 954/4885 |
| US-20250082628-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | IDH1, IDH3B, IDH2 | ATM 115/4885SLC5A2 1413/4885SLC5A1 819/4885 |
| US-20260014138-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | IDH3B, IDH1, IDH2 | ATM 114/4885SLC5A2 1376/4885SLC5A1 1033/4885 |
| US-20240148718-A1 | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) | IDH1, IDH3B, IDH2 | ATM 115/4885SLC5A2 1413/4885SLC5A1 819/4885 |
| US-20260000664-A1 | TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE-1 (IDH-1) MUTATION | IDH3B, IDH1, DNMT3A | ATM 28/4885SLC5A2 2405/4885SLC5A1 1875/4885 |
| US-11963956-B2 | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) | IDH1, IDH3B, IDH2 | ATM 115/4885SLC5A2 1413/4885SLC5A1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.